# FOURIER (evolocumab in people with cardiovascular disease)

Study · id `cardio:fourier` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: FOURIER; Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Browse, condition area: Coronary and vascular disease  

## In plain language

A large trial of 27,564 people with atherosclerotic cardiovascular disease and raised LDL cholesterol who already took a statin. Half also received evolocumab, an injected PCSK9 antibody, and half received placebo. Evolocumab lowered LDL cholesterol and reduced heart and blood-vessel events over a median of 2.2 years.

## Technical summary

Phase 3, randomized, double-blind, placebo-controlled trial (NCT01764633), 27,564 participants enrolled, started 2013-02-08 and primary completion 2016-11-11. The abstract reports the primary composite in 9.8% against 11.3% (hazard ratio 0.85, 95% CI 0.79 to 0.92). The paper says it was funded by Amgen, the registry lead sponsor. The registry lists dyslipidemia as the condition.

## Key facts

- Design: Allocation: randomized. Intervention model: parallel. Masking: quadruple. Primary purpose: treatment. (Registry values, in lower case.)
- Phase: Phase 3
- Enrolled: 27564 participants (enrolled count; Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Started: 2013-02-08 (actual) (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2016-11-11 (actual) (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Completion: 2016-11-11 (actual) (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2018-02-15 (actual) (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Estonia; Finland; France; Germany; Greece; Hungary; Iceland; India; Ireland; Israel; Italy; Japan; Latvia; Lithuania; Malaysia; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Portugal; Romania; Russia; Singapore; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Ukraine; United Kingdom; Hong Kong SAR China; Türkiye (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk, snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct01764633-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests evolocumab: Evolocumab (`cardio:evolocumab`)
- Official title names the effect of additional LDL cholesterol reduction: LDL cholesterol blood test (`cardio:ldl-cholesterol`)

## Provenance

Content hash: ffad9f7025cc112224e6880179a9095fa86dbe6d780c4d9114e5f860853b9d56
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14